A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B administered once daily for 28 days in subjects with partly controlled atopic asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pulmagen Therapeutics

Criteria

Inclusion Criteria:

• Partially controlled mild-moderate atopic asthma

• Receiving inhaled corticosteroids

• Non-smoker or former smoker

• Males and females aged 18 to 55 years inclusive

• If female, must be of non-childbearing potential

Exclusion Criteria:

• History of acute severe asthma attacks

• History of COPD

• Other serious respiratory or other medical condition which may interfere with the outcome of the study